Tissium raises €60M to expand surgical polymer tech
French medtech startup Tissium raised €30M in equity and secured up to €30M in debt to expand its surgical polymer platform.
Tissium is moving from platform science toward commercial-stage medtech. Its new financing shows investor appetite for technologies that can make surgery less invasive and tissue repair more precise.
What happened
French medtech startup Tissium raised €30M in equity funding and secured up to €30M in debt financing.
The company develops biomorphic programmable polymers that act as surgical adhesives to help reconstruct damaged tissue. The financing will support US rollout and further clinical trials.
Why it matters
This is a strong healthtech and medtech signal.
Tissium sits in a specialised part of healthcare where materials science, surgery and regulated product development meet. Moving from research platform toward commercial deployment is a major step for any medtech company.
The bigger picture
Some of the most valuable healthtech companies will not look like software companies. They will combine deep science, clinical validation and difficult regulatory execution to solve very specific medical problems.